Sangamo Therapeutics (SGMO) Announces Gene Therapy and Ex Vivo Gene-Edited Cell Therapy Data Presentations at ASH

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/13/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. MSFT
9. CRM
10. CRWV

Go back to Sangamo Therapeutics (SGMO) Announces Gene Therapy and Ex Vivo Gene-Edited Cell Therapy Data Presentations at ASH

Sangamo Therapeutics (SGMO) Tops Q3 EPS by 10c, Revenues Beat

November 6, 2019 4:49 PM EST

Sangamo Therapeutics (NASDAQ: SGMO) reported Q3 EPS of ($0.24), $0.10 better than the analyst estimate of ($0.34). Revenue for the quarter came in at $21.96 million versus the consensus estimate of $12.16 million.

We continue to prioritize and progress our clinical development programs, as demonstrated by the accepted ASH poster presentations for our two most advanced programs, SB-525... More